Intravitreal Dexamethasone Implant (Ozurdex) for Macular Edema Secondary to Retinal Vein Occlusion
نویسندگان
چکیده
1 Assistant Professor, Department of Ophthalmology, Eskisehir Osmangazi University Medical Faculty 2 Professor, Department of Ophthalmology, Eskisehir Osmangazi University Medical Faculty 3 Associate Professor, Department of Ophthalmology, Eskisehir Osmangazi University Medical Faculty 4 Medical Doctor, Department of Ophthalmology, Aksaray State Hospital 5 Medical Doctor, Department of Ophthalmology, Bilecik State Hospital 6 Associate Professor, Department of Biostatistics, Eskisehir Osmangazi University Medical Faculty
منابع مشابه
Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg
We report the case of a 62-year-old woman with a history of vitreoretinal surgery for vitreous hemorrhage secondary to central retinal vein occlusion (CRVO). Because of the persistence of macular edema (ME), she received 2 intravitreal injections of bevacizumab 0.5 mg (Avastin®, Genentech/Roche) three months after vitrectomy, without functional or anatomical improvement. Six months after vitrec...
متن کاملA New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®)
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion. By reporting this case we aimed to report a new side effect of 0.7 mg intravitreal dexamethasone implant that has not been reported in the literature before.
متن کاملCritical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
Macular edema is a common cause of visual loss in patients with retinal vein occlusions. Ozurdex(®), a dexamethasone intravitreal implant, has been shown in randomized controlled trials to reduce macular edema and improve visual acuity in patients with either branch retinal vein occlusions or central retinal vein occlusions. It was approved in the United States in 2009. Since then, new therapeu...
متن کاملRepeated Treatment for Macular Edema in Vein Occlusion by Intravitreal Implant of Dexamethasone
BACKGROUND Macular edema (ME) treatment has benefited from the recent intravitreal pharmacotherapy development of an intravitreal implant of dexamethasone (Ozurdex(®), Allergan, Irvine, Calif., USA). However, its efficiency has never been illustrated beyond 3 injections. CASE PRESENTATION We report the case of a 75-year-old woman with inferior branch vein occlusion, who, after laser photocoag...
متن کاملLocation of a Dexamethasone Implant at the Macula after Intravitreal Injection in a Silicone Oil-Filled Eye
Here, we report a case with cystoid macular edema (CME) due to central retinal vein occlusion (CRVO) presented with a dexamethasone implant (Ozurdex) trapped at the macula in her silicone oil- (SO-) filled eye after injection. No additional complications such as intraocular pressure (IOP) rise or retinal damage were observed. The CME was resolved during the follow-up period. At the last visit, ...
متن کاملComparison of Intravitreal Steroids for Treatment of Cystoid Macular Edema Due to Retinal Vein Occlusion
R etinal vein occlusion (RVO) causes vision loss mostly because of the development of intraretinal leakage that leads to macular edema. The treatment of cystoid macular edema (CME) secondary to RVO has evolved considerably during the past decade. Anti-VEGF agents have become the standard of care for CME secondary to both branch (BRVO) and central retinal vein occlusion (CRVO). Because the under...
متن کامل